Alternate theories for the mechanism of action of ILE in bupivacaine
toxicity have been suggested.
HTX-011 is a dual-acting, fixed-dose combination of the local anesthetic bupivacaine
with a low dose of the nonsteroidal anti-inflammatory drug meloxicam.
To compare the effect of intraperitoneal hydrocortisone with intraperitoneal bupivacaine
with regard to pain relief after laparoscopic cholecystectomy.
Twenty-one women were randomized to 0.5% bupivacaine
, 5 mL injected into the cervix at the 3 o'clock position, and 5 mL injected into at the 9 o'clock position to a depth of 3 cm, after anesthesia induction but before insertion of the uterine manipulator.
is the commonly used local anesthetic in caesarean deliveries.
The FDA had previously granted Breakthrough Therapy designation for HTX-011 based on the results of Phase 2 studies and two completed Phase 3 studies, which showed that HTX-011 produced significant reductions in both pain intensity and the need for opioids through 72 hours post-surgery compared to placebo and bupivacaine
solution, the standard-of-care.
The completed clinical studies included two Phase 3 studies in which HTX-011 demonstrated superior, sustained postoperative pain relief for 72 hours and decreased the need for opioids, with more patients who were opioid-free compared to placebo and bupivacaine
solution, the current standard-of-care, added the company.
After preloading with 10ml/kg of Ringers lactate, Group A received fixed dose of 10mg of 0.5% hyperbaric bupivacaine
, while Group B received dose according to height and weight using Harten's dose chart.
Malavika Prabhu, M.D., from Massachusetts General Hospital in Boston, and colleagues evaluated whether a liposomal bupivacaine
incisional block decreases postoperative pain after cesarean delivery.
Group I patients received 0.5% hyperbaric bupivacaine
for spinal anesthesia and Group II patients received 0.75% hyperbaric bupivacaine
Group 3: the patients received 1 ml/kg of 0.25% bupivacaine